Cyclohexane

Cyclohexane

SCHEMBL945649

C1CCCCC1.CC(Cl)Cl

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.67
TSHR P16473 1/20 0.67
TDP1 Q9NUW8 1/20 0.31
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclopropane SCHEMBL28633653 1.00
SCHEMBL126 0.82
SCHEMBL5438089 0.82
SCHEMBL11523834 0.82
SCHEMBL5728116 0.82
SCHEMBL3093207 0.78 ALDH1A1 (0.53) ALDH1A1TSHR
Cyclohexane SCHEMBL29188796 0.77 ALDH1A1 (0.50) ALDH1A1TSHRLMNA
Cyclopentane SCHEMBL20394153 0.76
Cyclohexane SCHEMBL457847 0.76 LMNA (0.57) ALDH1A1TSHRTDP1LMNA
SCHEMBL22394670 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117142991-A Method for preparing polyol carboxylic acid ester, polymerizable composition and adhesive 益丰新材料股份有限公司 2023-12-01 CN claimed
US-7485663-B2 Carvedilol TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-02-03 US claimed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 US claimed
US-20040225132-A1 Carvedilol HILDESHEIM JEAN (IL) 2004-11-11 US claimed
US-20020143045-A1 Carvedilol TEVA PHARMACEUTICALS USA, INC. 2002-10-03 US claimed
CN-117142991-A Method for preparing polyol carboxylic acid ester, polymerizable composition and adhesive 益丰新材料股份有限公司 2023-12-01 CN disclosed
WO-2011051975-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF PURE EPROSARTANAND ITS PHARMACEUTICAL ACCEPTABLE SALTS MATRIX LABORATORIES LTD (IN) 2011-05-05 WO disclosed
US-20110054186-A1 PROCESS FOR EPROSARTAN INTERMEDIATE HETERO RESEARCH FOUNDATION (IN) 2011-03-03 US disclosed
WO-2011004384-A2 PROCESS FOR THE PREPARATION OF EPROSARTAN GLOCHEM INDUSTRIES LIMITED (IN) 2011-01-13 WO disclosed
EP-2257540-A2 IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE Hetero Research Foundation (IN) 2010-12-08 EP disclosed
US-20100137613-A1 PROCESS FOR EPROSARTAN HETERO DRUGS LIMITED (IN) 2010-06-03 US disclosed
WO-2010023688-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF EPROSARTAN MATRIX LABORATORIES LIMITED (IN) 2010-03-04 WO disclosed
US-6699997-B2 REACTING 4-(OXIRAN-2-YLMETHOXY)-9H- CARBAZOLE WITH 2-(2-METHOXYPHENOXY)ETHYLAMINE TO PRODUCE CARVEDILOL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-03-02 US disclosed
US-20020143045-A1 Carvedilol TEVA PHARMACEUTICALS USA, INC. 2002-10-03 US disclosed
EP-0970073-A4 PROCESS FOR PREPARING EPROSARTAN SMITHKLINE BEECHAM CORP (US) 2001-01-24 EP disclosed
US-6172237-B1 Process for preparing eprosartan SMITHKLINE BEECHAM CORPORATION 2001-01-09 US disclosed
EP-0970073-A1 PROCESS FOR PREPARING EPROSARTAN SMITHKLINE BEECHAM CORPORATION (US) 2000-01-12 EP disclosed
WO-1998035963-A1 PROCESS FOR PREPARING EPROSARTAN SMITHKLINE BEECHAM CORPORATION (US) 1998-08-20 WO disclosed
US-5773592-A COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED MILLS RANDELL LEE (US) 1998-06-30 US disclosed
US-5428163-A Luminides; chemiluminescence; redox system, releasing free drug MILLS RANDELL L (US) 1995-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080260-A1 Preparation of prodrugs for selective drug delivery APEH, PAH, ALAD ALDH1A1 61/4885TSHR 3654/4885TDP1 2098/4885
US-20110054186-A1 PROCESS FOR EPROSARTAN INTERMEDIATE PTGER1, PTGER4, PDGFRA ALDH1A1 761/4885TSHR 226/4885TDP1 2656/4885
US-20100137613-A1 PROCESS FOR EPROSARTAN PTMA, PTGER1, PDGFRA ALDH1A1 732/4885TSHR 453/4885TDP1 2935/4885
US-20040225132-A1 Carvedilol REN, ADRB1, ADRB2 ALDH1A1 1694/4885TSHR 3165/4885TDP1 4010/4885
US-20020143045-A1 Carvedilol REN, ADRB1, ADRB2 ALDH1A1 1694/4885TSHR 3165/4885TDP1 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.